Clinical trials: sponsored by Fox Chase Cancer Center
Endometrial Cancer
Single Agent ONC201 in Recurrent or Metastatic Endometrial Cancer
ONC201 is a small molecule which selectively targets the G protein-coupled receptor DRD2. Downstream of target engagement, ONC201 activates the integrated stress response (ISR) in tumor cell leading to inactivation of Akt and…
- Trial name
- NCT03099499
- Testing
- ONC201
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- Fox Chase Cancer Center
Liver Cancer
Liver Cancer Community Education
This study proposes to bridge the gap between evidence and action and combat rising liver cancer rates attributed to Hepatitis B and C infection in Philadelphia by identifying neighborhoods with higher than expected rates of…
- Trial name
- NCT04272619
- Testing
- LIVE-R Life Education
- Where
- United States
- Volunteers
- 67 people, healthy volunteers welcome
- Sponsor
- Fox Chase Cancer Center
Gynecologic Cancer
Women's Health Communication Study
The central goal of this randomized, controlled pilot study is to examine the feasibility, acceptability, and preliminary effects of an educational intervention (called "Starting the Conversation"; STC) on patient communication…
- Trial name
- NCT05359952
- Testing
- Starting the Conversation, Sexual and Menopausal Health Resources Only
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- Fox Chase Cancer Center
Breast Cancer
Coping Together After Breast Cancer
The objective of the proposed study is to evaluate an Intimacy Enhancement (IE) intervention in 120 female early stage breast cancer survivors reporting sexual concerns and their intimate partners (240 total participants).
- Trial name
- NCT03930797
- Testing
- Intimacy Enhancement, Living Healthy Together
- Where
- United States
- Volunteers
- 240 people
- Sponsor
- Fox Chase Cancer Center
Recurrent Fallopian Tube Cancer, Recurrent Ovarian Epithelial Cancer
Paclitaxel and Ganetespib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
This phase I/II trial studies the side effects and best dose of ganetespib when given together with paclitaxel and to see how well they work in treating patients with recurrent ovarian, fallopian tube, or primary peritoneal…
- Conditions
- Recurrent Fallopian Tube Cancer, Recurrent Ovarian Epithelial Cancer, Recurrent Primary Peritoneal Cavity Cancer
- Trial name
- NCT01962948
- Testing
- paclitaxel, ganetespib, laboratory biomarker analysis
- Where
- 2 sites in United States
- Volunteers
- 12 people
- Sponsor
- Fox Chase Cancer Center
Major Liver Resection
Trial Using Octreotide to Enhance Liver Recovery After Hepatectomy
This will be a prospective, randomized, double blind trial enrolling patients who will undergo major liver resection. Patients will be randomized in a 1:1 ratio to receive either octreotide or placebo in the postoperative period.
- Trial name
- NCT03179995
- Testing
- Octreotide
- Where
- 2 sites in United States
- Volunteers
- 23 people
- Sponsor
- Fox Chase Cancer Center
Breast Cancer
Clinician Communication About Sexual Health
The objective of this study is to adapt a previously tested brief intervention aimed at enhancing clinicians communication about sexual health (iSHARE) to a mobile web-based platform showcasing a two-part podcast and to assess…
- Trial name
- NCT04262219
- Testing
- iShare
- Where
- United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Fox Chase Cancer Center
Sporadic Angiomyolipomas (AMLs)
Sporadic Angiomyolipomas (AMLs) Growth Kinetics While on Everolimus
The purpose of this research study is to see if oral everolimus is tolerable and effective in the treatment of sporadic Angiomyolipomas (AMLs). AMLs are the most common non-cancerous tumor of the kidney.
- Trial name
- SAGE (NCT02539459)
- Testing
- Everolimus
- Where
- 8 sites in United States
- Volunteers
- 20 people
- Sponsor
- Fox Chase Cancer Center
Soft-tissue Sarcoma
Study of TAK-228 (MLN0128) in Soft Tissue Sarcomas
This is an open-label phase II study of TAK-228 for patients ≥ 18 years of age with complex genomic sarcomas exhibiting Phosphoinositide-3 Kinase (PI3K) pathway dysregulation.
- Trial name
- NCT02987959
- Testing
- TAK-228
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Fox Chase Cancer Center
Adenocarcinoma of the Esophagus, Adenocarcinoma of the Gastroesophageal Junction
Bevacizumab and Combination Chemotherapy Before Surgery in Treating Patients With Locally Advanced Esophageal or Stomach Cancer
This pilot phase II trial studies how well giving bevacizumab and combination chemotherapy together before surgery works in treating patients with locally advanced esophageal or stomach cancer.
- Conditions
- Adenocarcinoma of the Esophagus, Adenocarcinoma of the Gastroesophageal Junction, Diffuse Adenocarcinoma of the Stomach, Intestinal Adenocarcinoma of the Stomach
- Trial name
- NCT01212822
- Testing
- bevacizumab, oxaliplatin, leucovorin calcium
- Where
- 3 sites in United States
- Volunteers
- 20 people
- Sponsor
- Fox Chase Cancer Center
Adult Angiosarcoma, Recurrent Adult Soft Tissue Sarcoma
Pazopanib Hydrochloride in Treating Patients With Advanced Angiosarcoma
This phase II trial studies how well pazopanib hydrochloride works in treating patients with advanced angiosarcoma. Pazopanib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
- Conditions
- Adult Angiosarcoma, Recurrent Adult Soft Tissue Sarcoma, Stage III Adult Soft Tissue Sarcoma, Stage IV Adult Soft Tissue Sarcoma
- Trial name
- NCT01462630
- Testing
- pazopanib hydrochloride, laboratory biomarker analysis, positron emission tomography
- Where
- 5 sites in United States
- Volunteers
- 29 people
- Sponsor
- Fox Chase Cancer Center
Head and Neck Cancer
Pemetrexed and Gemcitabine in Patients With Advanced Head and Neck Cancer
The purpose of this study is to look at how well the combination of two chemotherapy drugs, pemetrexed (Alimta) and gemcitabine (Gemzar) work to treat your cancer.
- Trial name
- NCT00394147
- Testing
- pemetrexed, gemcitabine
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Fox Chase Cancer Center
Carcinoma, Non-Small-Cell Lung
Study of Bevacizumab and Erlotinib in Patients With Advanced Non-small Cell Lung Cancer
This study will evaluate the combination of bevacizumab and erlotinib in elderly patients with advanced non-small cell lung cancer.
- Trial name
- NSCLC (NCT00553800)
- Testing
- bevacizumab, Erlotinib
- Where
- 7 sites in United States
- Volunteers
- 32 people
- Sponsor
- Fox Chase Cancer Center
Lymphoma, T-Cell, Peripheral
Study of MK-3475 Alone or in Combination With Copanlisib in Relapsed or Refractory NK and T-cell Non-Hodgkin Lymphoma
This is a multicenter, single-arm, open label, study consisting of two cohorts. Cohort 2 explores the combination of copanlisib and pembrolizumab in patients with relapsed or refractory NKTCL, who have received at least 1 prior…
- Trial name
- NCT02535247
- Testing
- MK-3475, Copanlisib
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Fox Chase Cancer Center
Cancer of Prostate
Bicalutamide With or Without Metformin for Biochemical Recurrence in Overweight or Obese Prostate Cancer Patients
Obesity and metabolic syndrome are prevalent among prostate cancer patients. Having an elevated insulin level in the blood is associated with a shorter median time to cancer progression and median overall survival in patients…
- Trial name
- BIMET-1 (NCT02614859)
- Testing
- Observation and Bicalutamide, Metformin and Bicalutamide
- Where
- 2 sites in United States
- Volunteers
- 29 people
- Sponsor
- Fox Chase Cancer Center
Colorectal Cancer
Regorafenib Plus 5-Fluorouracil/Leucovorin Beyond Progression in mCRC
This is a single arm open label pilot phase II trial of Regorafenib PO plus 5-FU/LV infusion in 15 mCRC patients who progressed on prior Regorafenib monotherapy as well as 5-FU containing chemotherapy combinations.The study will…
- Trial name
- NCT03099486
- Testing
- Regorafenib, 5-FU, Leucovorin
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Fox Chase Cancer Center
Lung Cancer
Combination Chemotherapy, Surgery, and Radiation Therapy in Treating Patients With Non-Small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells.
- Trial name
- NCT00043108
- Testing
- carboplatin, paclitaxel, conventional surgery
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- Fox Chase Cancer Center
Colorectal Neoplasms
Combination of Cetuximab, Capecitabine, and Oxaliplatin With or Without Bevacizumab
The purpose of this study is to determine the objective response rate of patients with previously untreated metastatic colorectal cancer treated with the combination of cetuximab, capecitabine, and oxaliplatin with out without…
- Trial name
- NCT00321100
- Testing
- bevacizumab, cetuximab, Oxaliplatin
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- Fox Chase Cancer Center
Relapsed or Refractory Solid Tumors, Nonsmall Cell Lung Cancer
Phase I/II Study of Lenalidomide Plus Pembrolizumab in Patients With Solid Tumors With Expansion in Non-small Cell Lung Cancer
For the phase I component of the trial a classic 3 + 3 dose escalation design will be utilized, with a fixed dose of pembrolizumab and an escalating dose of the lenalidomide.
- Trial name
- NCT02963610
- Testing
- Lenalidomide, Pembrolizumab
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Fox Chase Cancer Center
Liver Metastases, Mucinous Adenocarcinoma of the Colon
Chemoembolization Using Irinotecan in Treating Patients With Liver Metastases From Metastatic Colon or Rectal Cancer
RATIONALE: Drugs used in chemotherapy, such as irinotecan hydrochloride, work in different ways to stop the growth of tumor cells, either by killing the cells or stopping them from dividing.
- Conditions
- Liver Metastases, Mucinous Adenocarcinoma of the Colon, Mucinous Adenocarcinoma of the Rectum, Recurrent Colon Cancer
- Trial name
- NCT01285102
- Testing
- irinotecan-eluting beads, hepatic artery embolization
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Fox Chase Cancer Center